The randomised, phase II EBIN trial evaluated a total of 2 years of therapy, either with immunotherapy (nivolumab–ipilimumab for four cycles followed by nivolumab; arm A) or encorafenib–binimetinib for 3 months followed by immunotherapy, as per arm A (arm B) in 271 patients with BRAF-V600E/K unresectable stage III/IV melanoma. Here, BRAF is linked to melanoma.